Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was a meeting arranged by SvD Business and AktieTorget. The presentation was made in conjunction with Yield Life Science AB, one of the major owners of Isofol Medical.
The presentation is filmed by Finwire TV and can be viewed here as well as via AktieTorget.
Modufolin® (chemical name [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used folate-based drugs today including leucovorin and levoleucovorin and therefore does not require metabolic activation.
About Isofol Medical AB
Isofol Medical is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate is Modufolin®, a novel folate-based compound. Isofol Medical collaborates closely with its strategic R&D partner Merck and Cie, the world’s leading manufacturer of reduced folates including leucovorin and levoleucovorin.
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
Phone: +46 (0)707 646 500